TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Quince Therapeutics ( (QNCX) ).
Quince Therapeutics, Inc. hosted a Virtual Investor Day on October 2, 2025, where they presented information regarding IntraBio Inc.’s Phase 2 study for N-acetyl-L-leucine (NALL) in patients with ataxia-telangiectasia. During the event, Quince made a statement about the study’s unknown efficacy and failure across all endpoints, which was later removed from their presentation and video. This statement was based on an article from the European Journal of Paediatric Neurology, which indicated that while some symptoms improved, NALL did not significantly benefit motor function or ataxia symptoms. Quince advises investors not to rely on their initial statement.
The most recent analyst rating on (QNCX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Quince Therapeutics stock, see the QNCX Stock Forecast page.
Spark’s Take on QNCX Stock
According to Spark, TipRanks’ AI Analyst, QNCX is a Underperform.
Quince Therapeutics faces substantial financial challenges with no revenue, consistent losses, and negative cash flows, severely impacting its financial performance score. Technical analysis provides mixed signals, with some indicators suggesting potential momentum but overall bearish trends. Valuation remains unattractive due to the negative P/E ratio and lack of dividend yield. The absence of earnings call and corporate events data limits further insights.
To see Spark’s full report on QNCX stock, click here.
More about Quince Therapeutics
Average Trading Volume: 260,513
Technical Sentiment Signal: Buy
Current Market Cap: $103.7M
For an in-depth examination of QNCX stock, go to TipRanks’ Overview page.